European Commission targets alleged ‘pay-for-delay’ with pharma fines
20-06-2013
The UK Office of Fair Trading (OFT) has accused pharmaceutical firm GlaxoSmithKline (GSK) of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.
If you have already subscribed please login.
If you have any technical issues please email tech support.
GSK, market abuse, generic, Seroxat, OFT, competition, Alpharma, Norton Healthcare
